<DOC>
	<DOCNO>NCT01168895</DOCNO>
	<brief_summary>The purpose study compare safety pharmacokinetics ciprofloxacin inhalation single 52.5 48.75 mg dos COPD patient . In study 48.75 mg dose administer first time use new high dose strength ( i.e . one capsule contain 75 mg powder = 48.75 mg ciprofloxacin ) formulation . Safety investigation focus local tolerability lung evaluate whether patient inhale high amount powder compare low dose strength . Pharmacokinetics see body absorbs , distributes , break get rid study drug . Results study use decide whether new dose strength suitable large clinical trial plan COPD patient population .</brief_summary>
	<brief_title>Study COPD ( Chronic Obstructive Pulmonary Disease ) Subjects Investigate Safety , Tolerability , Pharmacokinetics Ciprofloxacin After Single Dose Inhalations 50 mg 75 mg Ciprofloxacin Inhalation Powder</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Adult subject COPD , 40 75 year age All subject must diagnosis COPD must airway obstruction postbronchodilator Forced Expiratory Volume 1 sec ( FEV1 ) &gt; /= 30 % &lt; = 80 % predict postbronchodilator FEV1 / Forced Vital Capacity ( FVC ) &lt; /= 70 % Subjects must current exsmokers smoke history 10 packyears Subjects must able perform technically acceptable pulmonary function test study period require protocol Subjects must able produce sufficient amount sputum sputum induction screen Subjects significant respiratory disease COPD . Exacerbation within 8 week prior screen Subjects 1 COPD exacerbation within 12 month prior screen Subjects must FEV1 least one Liter Subjects history physician 's diagnosis asthma . If patient total blood eosinophil count &gt; /= 0.6 x 10^9/L source documentation require verify increase eosinophil count relate nonasthmatic condition . Subjects hypersensitivity ciprofloxacin quinolones and/or inactive constituent inhalation powder Subjects know hypersensitivity bronchial system inhalation nebulized drug saline solution Subjects history cystic fibrosis Subjects clinically evident bronchiectasis Subjects take : Oral betaadrenergic drug non cardioselective beta blocker , Oral glucocorticoid , Antihistamines antileukotrienes prescribe asthma , Oral cromolyn sodium oral nedocromil sodium , Concomitant inhalative therapy antibiotic / concomitant systemic therapy fluoroquinolones</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>75 mg dose strength</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>